The National Institute for Health and Care Excellence recommends linzagolix, a new treatment for uterine fibroids, benefiting 30,000 adults in England and Wales. Two in three women develop uterine fibroids, with half experiencing symptoms. Linzagolix, taken as a daily tablet, can be offered for long-term treatment with or without hormonal add-back therapy. In the US, the FDA has approved Neffy, the first adrenaline nasal spray for emergency allergic reactions in adults and children over 30 kg. Neffy is administered as a single dose into one nostril. These new treatments offer hope for those suffering from uterine fibroids and severe allergic reactions.
Source link
Seven days in medicine: 14-20 August 2024
